Senti Biosciences Gets Bullish Analyst Coverage with 614% Upside Potential

H.C. Wainwright initiates Senti Bio with Buy rating and $12 target. Cancer therapy developer's CAR-NK platform shows promise for blood cancers and solid tumors.